Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Retained Earnings (2019 - 2025)

aTYR PHARMA's Retained Earnings history spans 7 years, with the latest figure at -$606.2 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 1515310.0% year-over-year to -$606.2 million; the TTM value through Dec 2025 reached -$606.2 million, down 1515310.0%, while the annual FY2025 figure was -$606.2 million, 1515310.0% down from the prior year.
  • Retained Earnings reached -$606.2 million in Q4 2025 per ATYR's latest filing, down from -$592.2 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $36000.0 in Q3 2024 to a low of -$606.2 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$299.1 million, with a median of -$374.1 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: soared 100.01% in 2024, then plummeted 1645102.78% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$263000.0 in 2021, then plummeted by 158696.2% to -$417.6 million in 2022, then fell by 12.07% to -$468.0 million in 2023, then surged by 99.99% to -$40000.0 in 2024, then crashed by 1515310.0% to -$606.2 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Retained Earnings are -$606.2 million (Q4 2025), -$592.2 million (Q3 2025), and -$566.5 million (Q2 2025).